Genomics Reporting Implementation Guide
3.0.0 - STU3 International flag

This page is part of the Genetic Reporting Implementation Guide (v3.0.0: STU3) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions

Example DiagnosticReport: somaticReport

Generated Narrative: DiagnosticReport somaticReport

Genetic analysis report (Genetics)

When For2023-02-02
Performers Practitioner Test Dolin Organization My Test Pathology Laboratories
Identifier Accession ID/23-0000345

Report Details

CodeValueFlagsNoteWhen ForReported
Genetic variant assessmentPresentFinal2023-02-01
Genetic variant assessmentPresentFinal2023-02-01
Genetic variant assessmentPresentFinal2023-02-01
Genetic variant assessmentPresentFinal2023-02-01
Genetic variant assessmentPresentFinal2023-02-01
Genetic variant assessmentPresentFinal2023-02-01
Genetic variant assessmentPresentFinal2023-02-01
Genetic variant assessmentPresentFinal2023-02-01
Diagnostic ImplicationFinal2023-02-01
Diagnostic ImplicationFinal2023-02-01
Diagnostic ImplicationFinal2023-02-01
Diagnostic ImplicationFinal2023-02-01
Diagnostic ImplicationFinal2023-02-01
Diagnostic ImplicationFinal2023-02-01
Diagnostic ImplicationFinal2023-02-01
Diagnostic ImplicationFinal2023-02-01
Therapeutic ImplicationFinal2023-02-01
Therapeutic ImplicationFinal2023-02-01
Therapeutic ImplicationFinal2023-02-01
Therapeutic ImplicationFinal2023-02-01
Therapeutic ImplicationFinal2023-02-01
Molecular ConsequenceFinal2023-02-01
Molecular ConsequenceFinal2023-02-01
Molecular ConsequenceFinal2023-02-01
Molecular ConsequenceFinal2023-02-01
Molecular ConsequenceFinal2023-02-01
Molecular ConsequenceFinal2023-02-01
Molecular ConsequenceFinal2023-02-01
Molecular ConsequenceFinal2023-02-01
Mutations/Megabase [# Ratio] in Tumor29.8Final2023-02-01
Microsatellite instability [Interpretation] in Cancer specimen QualitativeMSI-HFinal2023-02-01
PD-L1 by clone 22C3 in Tissue by Immune stain ReportPositiveFinal5% tumor proportion score2023-02-01
Haplotype NameHLA-A*24:02Final2023-02-012023-02-01 00:00:00-0500
Haplotype NameHLA-A*02:06Final2023-02-012023-02-01 00:00:00-0500
Haplotype NameHLA-B*35:01Final2023-02-012023-02-01 00:00:00-0500
Haplotype NameHLA-B*35:01Final2023-02-012023-02-01 00:00:00-0500
Haplotype NameHLA-C*03:03Final2023-02-012023-02-01 00:00:00-0500
Haplotype NameHLA-C*15:02Final2023-02-012023-02-01 00:00:00-0500

Patient is positive for Tier 1 / Level A variants, including variants with FDA-approved indications.

Coded Conclusions:

  • Positive